IL146131A0 - Treatment of neurotic disorders - Google Patents

Treatment of neurotic disorders

Info

Publication number
IL146131A0
IL146131A0 IL14613100A IL14613100A IL146131A0 IL 146131 A0 IL146131 A0 IL 146131A0 IL 14613100 A IL14613100 A IL 14613100A IL 14613100 A IL14613100 A IL 14613100A IL 146131 A0 IL146131 A0 IL 146131A0
Authority
IL
Israel
Prior art keywords
treatment
neurotic disorders
neurotic
disorders
Prior art date
Application number
IL14613100A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146131(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL146131A0 publication Critical patent/IL146131A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14613100A 1999-07-08 2000-07-07 Treatment of neurotic disorders IL146131A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (fr) 1999-07-08 2000-07-07 Traitement de troubles nevrotiques

Publications (1)

Publication Number Publication Date
IL146131A0 true IL146131A0 (en) 2002-07-25

Family

ID=8099796

Family Applications (5)

Application Number Title Priority Date Filing Date
IL14613100A IL146131A0 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders
IL146131A IL146131A (en) 1999-07-08 2001-10-23 Pharmaceutical compositions containing escitalopram for treatment of neurotic disorders
IL170193A IL170193A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170192A IL170192A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170194A IL170194A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL146131A IL146131A (en) 1999-07-08 2001-10-23 Pharmaceutical compositions containing escitalopram for treatment of neurotic disorders
IL170193A IL170193A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170192A IL170192A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170194A IL170194A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders

Country Status (38)

Country Link
US (6) US7271194B2 (fr)
EP (4) EP1200081B1 (fr)
JP (1) JP4773011B2 (fr)
KR (1) KR100604176B1 (fr)
CN (1) CN1198610C (fr)
AR (1) AR021155A1 (fr)
AT (1) ATE339955T1 (fr)
AU (6) AU782514B2 (fr)
BG (4) BG110468A (fr)
BR (1) BR0011578A (fr)
CA (4) CA2687396A1 (fr)
CL (3) CL2008003938A1 (fr)
CO (1) CO5190674A1 (fr)
CY (1) CY1105806T1 (fr)
CZ (1) CZ200270A3 (fr)
DE (1) DE60030861T2 (fr)
DK (1) DK1200081T3 (fr)
EA (1) EA006555B1 (fr)
ES (1) ES2272298T3 (fr)
HK (1) HK1048069B (fr)
HR (1) HRP20010820A2 (fr)
HU (1) HUP0201791A3 (fr)
IL (5) IL146131A0 (fr)
IS (1) IS6137A (fr)
ME (2) ME00032B (fr)
MX (1) MXPA01011626A (fr)
MY (1) MY143278A (fr)
NO (4) NO329021B1 (fr)
PL (1) PL352030A1 (fr)
PT (1) PT1200081E (fr)
SI (1) SI1200081T1 (fr)
SK (1) SK82002A3 (fr)
TR (4) TR200200014T2 (fr)
TW (1) TWI232101B (fr)
UA (1) UA77645C2 (fr)
WO (1) WO2001003694A1 (fr)
YU (1) YU78701A (fr)
ZA (1) ZA200108856B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
HUP0302778A3 (en) * 2000-07-21 2005-02-28 Lundbeck & Co As H Novel compounds and their use as glycine transport inhibitors
CA2445843A1 (fr) * 2001-05-01 2002-11-07 H. Lundbeck A/S Utilisation d'escitalopram pur enantiomere
ATE352546T1 (de) 2001-07-31 2007-02-15 Lundbeck & Co As H Kristalline zusammensetzung enthaltend escitalopram
WO2004004721A1 (fr) * 2002-07-08 2004-01-15 University Of Florida Utilisation d'inhibiteurs ssri visant a prevenir ou a attenuer les troubles psychologiques en rapport avec un traumatisme
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
KR20080080094A (ko) 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (fr) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
DK0612242T3 (da) 1991-11-15 2003-10-20 Sepracor Inc Anvendelse af ren S(+)-isomer af fluoxetin til fremstilling af et medikament mod migræne
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
PT759299E (pt) 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
CN1286687A (zh) * 1997-11-11 2001-03-07 H·隆德贝克有限公司 制备西酞普兰的方法
PT957099E (pt) * 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
EP1100501A4 (fr) * 1998-06-30 2002-12-04 Lilly Co Eli Pyrrolidine et derives de pyrrolidine influen ant les systemes associes a la serotonine
AU771252B2 (en) 1998-07-13 2004-03-18 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression and other disorders
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
CA2337507A1 (fr) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition pour le traitement du stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
WO2000023431A1 (fr) * 1998-10-20 2000-04-27 H. Lundbeck A/S Methode de preparation du citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
IL145615A0 (en) * 1999-04-14 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6469064B2 (en) * 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
CA2445843A1 (fr) * 2001-05-01 2002-11-07 H. Lundbeck A/S Utilisation d'escitalopram pur enantiomere

Also Published As

Publication number Publication date
TR200402277T2 (tr) 2005-01-24
PL352030A1 (en) 2003-07-28
CN1360501A (zh) 2002-07-24
EP1440690A3 (fr) 2004-08-18
AU2005202685B2 (en) 2009-01-15
DE60030861D1 (de) 2006-11-02
NO20100335L (no) 2002-01-07
PT1200081E (pt) 2007-01-31
BG110466A (en) 2010-01-29
HRP20010820A2 (en) 2003-08-31
JP2003504332A (ja) 2003-02-04
US20050101665A1 (en) 2005-05-12
ATE339955T1 (de) 2006-10-15
DE60030861T2 (de) 2007-05-03
BR0011578A (pt) 2002-03-26
EP1440690A2 (fr) 2004-07-28
US7265151B2 (en) 2007-09-04
EP1440689A2 (fr) 2004-07-28
SK82002A3 (en) 2002-07-02
ZA200108856B (en) 2002-12-24
BG110468A (en) 2010-01-29
AR021155A1 (es) 2002-06-12
EP1440689A3 (fr) 2004-08-25
TR200402276T2 (tr) 2005-01-24
HK1048069B (zh) 2005-12-16
CA2687396A1 (fr) 2001-01-18
US7271194B2 (en) 2007-09-18
NO20100334L (no) 2002-01-07
HUP0201791A3 (en) 2005-02-28
TWI232101B (en) 2005-05-11
EA006555B1 (ru) 2006-02-24
ME00032B (fr) 2010-02-10
CL2008003939A1 (es) 2009-06-05
KR20020015346A (ko) 2002-02-27
IL170192A (en) 2010-04-29
CL2008003941A1 (es) 2009-05-22
BG106279A (bg) 2002-08-30
WO2001003694A1 (fr) 2001-01-18
CA2373757C (fr) 2010-01-05
IS6137A (is) 2001-10-30
NO329021B1 (no) 2010-07-26
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (fr) 2004-07-28
CA2687392A1 (fr) 2001-01-18
MXPA01011626A (es) 2002-06-04
US20040029956A1 (en) 2004-02-12
TR200402275T2 (tr) 2005-03-21
US20040029958A1 (en) 2004-02-12
CO5190674A1 (es) 2002-08-29
HUP0201791A2 (en) 2002-10-28
CA2373757A1 (fr) 2001-01-18
HK1048069A1 (en) 2003-03-21
IL146131A (en) 2007-02-11
IL170194A (en) 2010-05-31
US20040029957A1 (en) 2004-02-12
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
YU78701A (sh) 2004-03-12
US6960613B2 (en) 2005-11-01
KR100604176B1 (ko) 2006-07-25
EP1200081B1 (fr) 2006-09-20
MEP2508A (xx) 2010-02-10
CL2008003938A1 (es) 2009-05-22
CA2687394A1 (fr) 2001-01-18
CZ200270A3 (cs) 2002-04-17
US20020086899A1 (en) 2002-07-04
CN1198610C (zh) 2005-04-27
EP1440691A3 (fr) 2004-08-25
EA200200137A1 (ru) 2002-06-27
ES2272298T3 (es) 2007-05-01
AU2005202686A1 (en) 2005-07-14
BG110467A (en) 2010-01-29
UA77645C2 (en) 2007-01-15
AU2008264188A1 (en) 2009-05-07
DK1200081T3 (da) 2006-12-27
AU2008264182A1 (en) 2009-01-29
MY143278A (en) 2011-04-15
AU2005202685A1 (en) 2005-07-14
NO20020062D0 (no) 2002-01-07
IL170193A (en) 2010-04-29
AU2005202686B2 (en) 2009-01-15
JP4773011B2 (ja) 2011-09-14
TR200200014T2 (tr) 2002-05-21
AU782514B2 (en) 2005-08-04
EP1200081A1 (fr) 2002-05-02
NO20100333L (no) 2002-01-07
AU2005202684B2 (en) 2009-01-15
AU5806100A (en) 2001-01-30
US20070276035A1 (en) 2007-11-29
CY1105806T1 (el) 2011-02-02

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
EP1063990A4 (fr) Therapie destinee aux troubles lies aux oestrogenes
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
ZA200108856B (en) Treatment of neurotic disorders.
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB9926968D0 (en) Treatment of neurological disorders
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU7106300A (en) Treatment of skin disorders
GB2360453B (en) Treatment of skin conditions
HUP0102886A3 (en) Treatment of anxiety disorders
AR026062A1 (es) Tratamiento de desordenes oculares
IL131347A0 (en) Treatment of skin disorders
GB0101146D0 (en) Treatment of skin conditions
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
AU2004235661B2 (en) Methods of treatment of mitochondrial disorders
GB9924942D0 (en) Treatment of movement disorders
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
GB9815188D0 (en) Treatment of skin disorders
GB0017951D0 (en) Treatment of movement disorders
GB0024704D0 (en) Treatment of hyperproliferative skin disorders
GB9923551D0 (en) Treatment of neuropsychiatric disorders
GB9914101D0 (en) Treatment of oils
GB9914106D0 (en) Treatment of oils
GB9914103D0 (en) Treatment of oils